Edited by: Alexei Tepikin, University of Liverpool, United Kingdom
Reviewed by: Jason I. E. Bruce, The University of Manchester, United Kingdom; Pawel Ferdek, Jagiellonian University, Poland
This article was submitted to Gastrointestinal Sciences, a section of the journal Frontiers in Physiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
C-reactive protein level (CRP) and white blood cell count (WBC) have been variably used in clinical trials on acute pancreatitis (AP). We assessed their potential role.
First, we investigated studies which have used CRP or WBC, to describe their current role in trials on AP. Second, we extracted the data of 1435 episodes of AP from our registry. CRP and WBC on admission, within 24 h from the onset of pain and their highest values were analyzed. Descriptive statistical tools as Kruskal–Wallis, Mann–Whitney
Our literature review showed extreme variability of CRP used as an inclusion criterion or as a primary outcome or both in past and current trials on AP. In our cohort, CRP levels on admission poorly predicted mortality and severe cases of AP; AUC: 0.669 (CI:0.569–0.770); AUC:0.681 (CI: 0.601–0.761), respectively. CRP levels measured within 24 h from the onset of pain failed to predict mortality or severity; AUC: 0.741 (CI:0.627–0.854); AUC:0.690 (CI:0.586–0.793), respectively. The highest CRP during hospitalization had equally poor predictive accuracy for mortality and severity AUC:0.656 (CI:0.544–0.768); AUC:0.705 (CI:0.640–0.769) respectively. CRP within 24 h from the onset of pain used as an inclusion criterion markedly increased the combined event rate of mortality and severe AP (13% for CRP > 25 mg/l and 28% for CRP > 200 mg/l).
CRP within 24 h from the onset of pain as an inclusion criterion elevates event rates and reduces the number of patients required in trials on AP.
Acute pancreatitis (AP) is one of the most common acute gastrointestinal pathology needing hospitalization in the United States (
There are few clinical trials on AP despite its burden (
High-quality clinical trials on AP are difficult to conduct as the most important clinical outcomes, such as severe acute pancreatitis (SAP) and death, have low event rates (
The most obvious and simplest markers of inflammation are C-reactive protein level (CRP) and white blood cell count (WBC). They are widely available and readily reported in nearly any healthcare settings. Therefore, trials on AP have been using inflammatory markers as inclusion criteria and as primary outcomes too. However, there is no currently available evidence-based information and practical guideline on their use.
Our aim was to assess the past and current role of CRP and WBC in clinical trials on AP and to provide evidence from a high-quality large multinational cohort analysis to guide clinical researchers on the most appropriate role of CRP and WBC in future clinical trials.
First, we reviewed the studies on AP that have used CRP or WBC as inclusion criterion or as an outcome to understand their past and current role.
Second, we analyzed data from a large prospectively collected cohort of AP patients to assess the potential future role of CRP and WBC in the design of trials.
We searched PubMed on January 9, 2019 for the query: random∗ AND “acute pancreatitis.” The records were managed by EndNote X7.4, software (Clarivate Analytics, Philadelphia, PA, United States). Studies published before January 1, 2000 were excluded. The records were screened by title, by abstract and by full text.
In addition, we searched the study registries
Studies from both searches were selected that used CRP or WBC as an inclusion criterion or primary outcome in trials on AP.
The aggregated yield of both search strategies was screened and data were extracted on the role, timing, and thresholds of CRP and WBC.
Subjects with AP were enrolled in our large multicentric and multinational registry on AP hospitalization from 13 countries and 29 centers (
Acute pancreatitis was defined as the presence of at least two of the following criteria: abdominal pain, at least threefold rise in the pancreatic enzymes and evidence of pancreatitis on imaging (
This database includes data from multiple centers and all contributing centers complied with all the necessary laboratory requirements and guidelines. CRP and WBC were uploaded onto the prospective database in units of mg/l and G/l, respectively. If local measurements used different units then the results were calculated and recorded in the above units.
We extracted data on the onset of pain, CRP, WBC, demographics (age and gender) and etiology, severity, and mortality of AP. Data extraction included patients enrolled between August 2012 and September 2017.
Prior to the analysis of the dataset, descriptive statistical tools were used to describe the basic characteristics. To observe differences between the severity groups, we applied Kruskal–Wallis test with Mann–Whitney
Our search criteria yielded a total of 2021 records. After the exclusion of studies from before 2000, there were 1664 left. After screening by title 136 eligible abstracts remained and 107 full-text articles were reviewed. This strategy identified 17 studies where CRP was an inclusion criterion, 10 studies where CRP was a primary outcome (
We found three studies on
Furthermore, CRP was used as a variable inclusion criterion. Twelve studies used a cut off level of 150 mg/l, four studies 120 mg/l, and three studies 100 mg/l (NCT00894907, NCT03082469). One study specified a cut off level at 120 mg/l within 24 h from admission and 200 mg/l within 48 h from admission and another study just mentions elevated CRP. One study required high CRP on admission, two studies within 24, and one study within 48 h from admission. From the onset of symptoms six studies required CRP within 48 (NCT00894907, NCT03082469), four studies within 72, one study within 120 h and six studies did not specify the timeframe. The details and the references are shown in the
White blood cell count is used as an optional inclusion criterion only in two studies with a cut off level of > 16G/l.
Our analysis included data of 1435 episodes of AP. We had 100% data on age, gender, severity, mortality, and length of hospitalization. WBC and CRP on admission were available in 1288 (89.9%) and 1177 cases (82.0%), respectively. WBC and CRP, within 24 h from the onset of pain, were available in 691 (48.2%) and in 627 patients (43.7%) respectively. There were 79 (5.51%) severe, 371 (25.85%) moderately severe, 985 (68.64%) mild AP, and altogether 34 patients died (2.37%). The details of the descriptive statistics (demographics, etiology) of the cohort are shown in the
On admission median CRPs were directly associated with the severity of AP, 14.90 (IQR: 5.00–54.60) mg/l in mild, 26.90 (IQR: 6.93–105.95) mg/l in moderately severe, and 83.30 (IQR: 13.50–222.70) mg/l in severe (mild vs. moderately severe,
On admission CRP;
Receiver Operating Characteristic analyses showed poor predictive accuracy of CRP on admission for mortality and severe AP, AUC: 0.669 (CI: 0.569–0.770) (
On admission median WBC counts were significantly lower in mild AP 11.70 (IQR: 9.16–14.80) G/l, than in moderately severe 14.00 (IQR: 10.50–17.54) G/l and 15.24 (IQR: 11.30–17.95) G/l in severe AP (mild vs. moderately severe AP,
ROC analyses showed poor predictive accuracy of WBC on admission for mortality, severe and mild AP, AUC: 0.648 (CI: 0.546–0750) (
Median CRP within 24 h from the onset of pain were significantly lower in mild 8.90 (IQR: 3.60–25.10) mg/l and moderately severe 14.60 (IQR: 4.15–60.46) mg/l, than in severe AP 51.45 (IQR: 7.85–175.53) mg/l (mild vs. moderately severe AP:
C-reactive protein level within 24 h from the onset of pain;
Receiver Operating Characteristic analyses showed a fair predictive accuracy of CRP within 24 h for mortality AUC: 0.741 (CI: 0.627–0.854) (
Median of the WBC within 24 h from the onset of pain was significantly lower in mild 11.70 (IQR: 9.24–14.32) G/l, than in moderately severe 14.55 (IQR: 10.80–17.51) G/l and in severe AP 14.60 (IQR: 11.45–18.07) G/l (mild vs. moderately severe AP,
ROC analyses showed poor predictive accuracy of WBC within 24 h for mortality, severe and mild AP, AUC: 0.616 (CI: 0.490–0.742) (
Although CRP cannot predict the severity or mortality of AP, higher levels on admission increase the event rate of mortality and severity and their composite. However, a decreasing proportion of AP patients have higher levels of CRP and WBC on admission (
The association between on admission C-reactive protein levels (CRP) and white blood cell count (WBC) and the severity and mortality of acute pancreatitis.
Limiting the on admission CRP and WBC to patients who presented within 24 h from the onset of the pain, the potential number of subjects dropped, but severity and mortality were higher compared to all admissions (
The association between C-reactive protein levels (CRP) and white blood cell count (WBC) within 24 h from the onset of pain and the severity and mortality of acute pancreatitis.
White blood cell count did not show a clear relationship with the outcomes of AP regardless of the timing of the measurement (
Analysis of the homoscedasticity of CRP and WBC for the duration of pain revealed that there were significant differences between the homoscedasticity of the CRP on day 1, 2, and 4, the details are in
Median of maximum CRP was significantly lower in mild, 95.18 (IQR: 28.73–175.53) mg/l and in moderately severe 213.20 (IQR: 119.20–292.00) mg/l, than in severe AP 232.90 (IQR: 147.50–333.95) mg/l (mild vs. moderately severe AP,
Maximum CRP during hospitalization;
Receiver Operating Characteristic analyses showed a poor predictive accuracy of maximum CRP for mortality AUC: 0.656 (CI: 0.544–0.768) (
Median of maximum WBC was directly associated with the severity of AP, 12.49 (IQR: 9.55–15.68) G/l in mild, 16.16 (IQR: 12.00–20.59) G/l in moderately severe, and 18.63 (IQR: 13.12–24.30) G/l in severe (mild vs. moderately severe AP,
Receiver Operating Characteristic analyses for maximum WBC showed fair predictive accuracy for mortality and severe AP, AUC: 0.753 (CI: 0.662–0.843) (
The results of our review proved that CRP is widely used in studies as an inclusion criterion or primary outcome. CRP is more commonly used as an inclusion criterion and its use is highly variable in terms of threshold and timing.
The first study on the role of CRP in the prediction of the outcome of AP was published by
In most studies where CRP is an inclusion criterion the authors argue that CRP is a predictor of severe disease based on past evidence and cite a consensus article from 1999 by
More recently the largest study on the assessment of CRP in AP included 172 patients (
There is only one study analyzing the role of CRP in AP, since the introduction of revised Atlanta classification, but this is from a tertiary referral center, where patients were admitted within 14 days from the onset of disease and there were only 50 subjects enrolled (
In view of the above arguments and the findings of our literature search, it is clear that CRP is widely used, but there is a far too great and unjustified variability of its use both in terms of threshold and its timing.
Based on the results of our analysis, neither CRP nor WBC can predict mortality or severe disease on the day of admission, even if they are restricted to patients who present within less than 24 h from the onset of the pain. The AUC for the predictive value of CRP and WBC regardless their timing did not exceed 0.8, therefore a cut-off cannot be determined and they should not be used to predict severity or mortality.
If we accept that studies should aim to analyze effects of interventions in the early phase of AP as the disease course may more likely to be influenced, then we have to assess the potential role of any inclusion criteria on admission and as soon as possible from the onset of symptoms.
We have shown that CRP limited within 24 h from the onset of pain can increase the homoscedasticity (
In order to have the best evidence in the treatment of AP we believe that mortality and severe disease should be the endpoints of high-quality trials.
Our data clearly demonstrates that we would be able to reduce the number of participants in the study by increasing the inclusion CRP levels, but we would need to screen an increasing population to find the eligible subjects as less and less subjects would fit the inclusion criterion for enrollment (
To demonstrate the clinical relevance and potential use of our findings, we calculated the sample sizes for a hypothetical study on AP, in which we would like to demonstrate a 50% reduction of the composite endpoint with 80% statistical power and a
Based on the composite endpoints of severe acute pancreatitis (AP) for the CRP levels within 24 h form the onset of pain in our cohort we calculated the sample size for a hypothetical study on AP, in which we would like to demonstrate a 50% reduction of the composite endpoint with 80% statistical power and a
0< | 627 | 100 | 39 | 6 | – | – |
25< | 194 | 31 | 25 | 13 | 326 | 1052 |
50< | 131 | 21 | 17 | 13 | 326 | 1552 |
75< | 97 | 15 | 14 | 14 | 300 | 2000 |
100< | 72 | 11 | 11 | 15 | 278 | 2527 |
125< | 59 | 9 | 11 | 19 | 212 | 2356 |
150< | 41 | 7 | 9 | 22 | 178 | 2543 |
175< | 31 | 5 | 8 | 26 | 145 | 2900 |
200< | 25 | 4 | 7 | 28 | 132 | 3300 |
We would recommend that clinical researchers use CRP within 24 h from the onset of pain as an inclusion criterion. In the design process the researchers should set the threshold of inclusion CRP depending on the practicalities and feasibility of the planned study.
Our results demonstrate that the highest detected CRP and WBC during the course of AP cannot predict the severity or mortality of the disease (AUC < 0.8) (
Here we provide high-quality evidence and a method how to decrease the number of patients required for clinical trials on AP. We demonstrate that by increasing the CRP levels measured within 24 h from the onset of abdominal pain as an inclusion criterion we can elevate the event rates of mortality, and severity. Investigators can set the inclusion CRP level tailored for their study purposes and can test feasibility. Importantly, our data proves that CRP should not be used as a primary outcome. Finally, WBC should not be used neither as an inclusion criterion nor as an outcome in clinical trials on AP.
The datasets generated for this study are available on request to the corresponding author.
The studies involving human participants were reviewed and approved by Scientific and Research Ethics Committee of the Medical Research Council on August 15, 2012 (22254-1/2012/EKU). The patients/participants provided their written informed consent to participate in this study.
NF and PH designed the research and study concept. NF and LH performed the data extraction and analyzed and interpreted the data. NF, LH, BE, and PH wrote the article. ÁV, AS, ED, and PH supervised the study. AlM, JB, PS, JC, ÁV, SzG, DP, PV, KM, PJH, BE, TT, LC, BN, DI, BK, ED, FI, AH, VD-V, LG, JH, MP, IF, KF, MV, KC, IT, FH-P, ArM, EM, VS, JN, AI, ShG, BB, JS, PP, and ASzep enrolled and managed the patients and also conducted a critical revision of the manuscript for important intellectual content. All of the co-authors granted final approval for the manuscript.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The Supplementary Material for this article can be found online at: